α2-MACROGLOBULIN AND REDUCED BASEMENT-MEMBRANE DEGRADATION IN DIABETES

Michael Brownlee

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Thickening of the capillary basement membrane is the fundamental morphological alteration of diabetic microangiopathy. Leucocyte neutral proteases can degrade basement membrane in vivo. The activity of a purified neutral protease from granulocytes is inhibited by α2-macroglobulin. It is suggested that the reported increase in the concentration of α2-macroglobulin in the blood of diabetic patients inhibits the activity of leucocyte neutral proteases which normally degrade basement membrane. The resultant decreased rate of breakdown would contribute to the increase in basement-membrane material seen in diabetes.

Original languageEnglish (US)
Pages (from-to)779-780
Number of pages2
JournalThe Lancet
Volume307
Issue number7963
DOIs
StatePublished - Apr 10 1976
Externally publishedYes

Fingerprint

Macroglobulins
Basement Membrane
Peptide Hydrolases
Leukocytes
Diabetic Angiopathies
Granulocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

α2-MACROGLOBULIN AND REDUCED BASEMENT-MEMBRANE DEGRADATION IN DIABETES. / Brownlee, Michael.

In: The Lancet, Vol. 307, No. 7963, 10.04.1976, p. 779-780.

Research output: Contribution to journalArticle

Brownlee, Michael. / α2-MACROGLOBULIN AND REDUCED BASEMENT-MEMBRANE DEGRADATION IN DIABETES. In: The Lancet. 1976 ; Vol. 307, No. 7963. pp. 779-780.
@article{ad24ce19cfed41c6a79884e869aab8fd,
title = "α2-MACROGLOBULIN AND REDUCED BASEMENT-MEMBRANE DEGRADATION IN DIABETES",
abstract = "Thickening of the capillary basement membrane is the fundamental morphological alteration of diabetic microangiopathy. Leucocyte neutral proteases can degrade basement membrane in vivo. The activity of a purified neutral protease from granulocytes is inhibited by α2-macroglobulin. It is suggested that the reported increase in the concentration of α2-macroglobulin in the blood of diabetic patients inhibits the activity of leucocyte neutral proteases which normally degrade basement membrane. The resultant decreased rate of breakdown would contribute to the increase in basement-membrane material seen in diabetes.",
author = "Michael Brownlee",
year = "1976",
month = "4",
day = "10",
doi = "10.1016/S0140-6736(76)91614-7",
language = "English (US)",
volume = "307",
pages = "779--780",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "7963",

}

TY - JOUR

T1 - α2-MACROGLOBULIN AND REDUCED BASEMENT-MEMBRANE DEGRADATION IN DIABETES

AU - Brownlee, Michael

PY - 1976/4/10

Y1 - 1976/4/10

N2 - Thickening of the capillary basement membrane is the fundamental morphological alteration of diabetic microangiopathy. Leucocyte neutral proteases can degrade basement membrane in vivo. The activity of a purified neutral protease from granulocytes is inhibited by α2-macroglobulin. It is suggested that the reported increase in the concentration of α2-macroglobulin in the blood of diabetic patients inhibits the activity of leucocyte neutral proteases which normally degrade basement membrane. The resultant decreased rate of breakdown would contribute to the increase in basement-membrane material seen in diabetes.

AB - Thickening of the capillary basement membrane is the fundamental morphological alteration of diabetic microangiopathy. Leucocyte neutral proteases can degrade basement membrane in vivo. The activity of a purified neutral protease from granulocytes is inhibited by α2-macroglobulin. It is suggested that the reported increase in the concentration of α2-macroglobulin in the blood of diabetic patients inhibits the activity of leucocyte neutral proteases which normally degrade basement membrane. The resultant decreased rate of breakdown would contribute to the increase in basement-membrane material seen in diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0017104716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017104716&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(76)91614-7

DO - 10.1016/S0140-6736(76)91614-7

M3 - Article

C2 - 56592

AN - SCOPUS:0017104716

VL - 307

SP - 779

EP - 780

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 7963

ER -